U.S. FDA approves AbbVie's drug for Parkinson's disease
The drug tavapadon, which AbbVie gained access to through its $8.7 billion acquisition of Cerevel Therapeutics in 2023, comes as a once-a-day pill
On September 25, 2026, the U.S. Food and Drug Administration (FDA) approved AbbVie's drug, Juvmo, for the treatment of Parkinson's disease in adults. The medication, known by its generic name tavapadon, is available as a once-daily oral tablet and was developed through AbbVie's acquisition of Cerevel Therapeutics in 2023. Parkinson's disease is a progressive neurological condition affecting movement, causing tremors, stiffness, and balance problems, with over 11 million people affected globally.
Juvmo functions by artificially replenishing dopamine, a crucial neurotransmitter that diminishes in individuals with Parkinson's. The FDA's approval was predicated on findings from AbbVie's late-stage trial data indicating improved symptom management in patients. The most frequently reported side effects in these trials were nausea, dizziness, and headaches.
While AbbVie has not disclosed the pricing or launch strategy, Citi analysts anticipated the drug's introduction in the third quarter of 2026, with potential gradual uptake as discussions on Medicare coverage unfold. AbbVie aims for over $5 billion in Parkinson's disease sales post-launch.
Written by urgent.news from The Hindu Health's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
